This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights AstraZeneca, Caterpillar, Crown Castle, Nasdaq and American Water Works
by Zacks Equity Research
AstraZeneca, Caterpillar, Crown Castle, Nasdaq and American Water Works are part of the Zacks top Analyst Blog.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.
Universal Health (UHS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Universal Health's (UHS) Q3 results are likely to reflect sound segmental performances resulting from a constant pursuit of expansion moves. However, high labor costs might partly offset the results.
Top Stock Reports for AstraZeneca, Caterpillar & Crown Castle
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), Caterpillar Inc. (CAT) and Crown Castle Inc. (CCI).
Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Astrazeneca (AZN) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $54.35, moving -0.29% from the previous trading session.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $55.53, marking a +0.84% move from the previous day.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $55.07, marking a -0.42% move from the previous day.
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe
by Zacks Equity Research
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks
by Zacks Equity Research
Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $55.55 in the latest trading session, marking a +1.29% move from the prior day.
Zacks.com featured highlights include Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity
by Zacks Equity Research
Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity have been highlighted in this Screen of The Week article.
5 Dividend Growth Stocks to Beat Market Volatility
by Sweta Killa
Coca-Cola (KO), General Dynamics (GD), AstraZeneca (AZN), Boise Cascade (BCC), and Insperity (NSP) that offer dividend growth could be compelling picks amid market volatility.
AZN vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AZN vs. LLY: Which Stock Is the Better Value Option?
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why
by Zacks Equity Research
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.
3 Medical Stocks Displaying Remarkable Relative Strength in 2022
by Derek Lewis
In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
by Zacks Equity Research
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
by Kinjel Shah
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
Astrazeneca (AZN) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $56.31, moving -0.23% from the previous trading session.
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
by Zacks Equity Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID
by Zacks Equity Research
Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
by Zacks Equity Research
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Top Analyst Reports for Apple, Amazon.com & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and AbbVie Inc. (ABBV).